BriaCell Extends Personalized Breast Cancer Immunotherapy To Prostate & Lung Cancer And Melanoma

by Vandana Singh, Benzinga Editor

June 16, 2021 9:28 AM | 26 seconds read | Make a Comment

BriaCell Therapeutics Corp BCTX has advanced its targeted oncology therapeutics into several novel immunotherapy cell lines, including - Bria-Pros for prostate cancer, Bria-Mel for melanoma, and Bria-Lung for lung cancer.
The company anticipates commencing clinical trials for these novel therapies in 2022.
Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer, remains on track to commence patient dosing in 2021.
Price Action: BCTX shares are up 11.1% at $6.70 during the premarket session on the last check Wednesday.

Posted In: Biotech News Health Care General breast cancer Briefs melanoma

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.